CAMBRIDGE, Mass., Jan. 3, 2023
/PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a
biopharmaceutical company with the purpose to better the lives of
people impacted by kidney disease, granted one newly-hired employee
options to purchase an aggregate of 2,000 shares of Akebia's common
stock on December 30, 2022, as an
inducement material to such employee entering into employment with
Akebia. The options were granted in accordance with Nasdaq Listing
Rule 5635(c)(4).
The options have an exercise price of $0.58 per share, which is equal to the closing
price of Akebia's common stock on the grant date. The stock options
vest over four years, with 25% of the shares vesting on the first
anniversary of the grant date and the remaining 75% of shares
vesting quarterly thereafter, in each case, subject to the new
employee's continued service with Akebia. Each stock option has a
10-year term and is subject to the terms and conditions of Akebia's
inducement award program and a stock option agreement covering the
grant.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated
biopharmaceutical company with the purpose to better the lives of
people impacted by kidney disease. Akebia was founded in 2007 and
is headquartered in Cambridge,
Massachusetts. For more information, please visit our
website at www.akebia.com, which does not form a part of this
release.
Akebia Therapeutics Contact
Mercedes
Carrasco
mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301712684.html
SOURCE Akebia Therapeutics